CERo Therapeutics Holdings Inc (CERO)

and the last post your made was in dec 2025 which was 6 months ago. you must be some AI market maker who is running the stock. you replied to my post and to posted any comment for over 6 months that is how abandoned market the otcmrket is since the BAN by brokers since 20222.. 95% of retail traders and investors cannot buy, they can only sell even if they owned it. i don't know what the SEC is think to have where you have broker bannning people from buying stocks that is SEC reporting.

*and this stock or company is more legit than a lot of stocks that are currently trading in the Nasdaq.



theese company wanted to be delisted to otcmarkets. ...retail investors have to sell if theybought shares in brokers who ban trading it. you can only sell these stocks.

exactly, it one large investor and insider management who owns the company. and stand to make millions if the uplist to nasdaq which is easy. nasdaq is a corrupt exchange, if you give them $325,000 which is a ripoff they will let you list your shares on nasdaq. as for options they've arrranged it so insiders management get to make millions if FDA approval. with no risk what exchange wants $325,000 to list their shares.otc market is free or cost only $5000 bucks. it because many firms don't trade or invest in stocks listed in the otcmarket.
And ths stock was just share selling shre dilution scheme. I don't know how much money they are making now trading the otc but it's fraction of hte money that they were making when it was trading in the nasdaq. otcmarkets is not the same marke as it was before 2022/ many brokers ban customers from buying or tradin in the otc market. they can keep diluting the shares but for what.
insiders and board of directors and that one investor probably owns 90% of the share by now. it had what less than 10 million shares last year now has 54 million that is 90% dilution. as for bankruptcy, biotechs don't go bankrupt when they have a drug in the pipeline. they go bankrupt if their drug is not approved. and that one investor backs off. and stop investing in the company and shut down the company. that one investor invested over 50 million in this company over the years. in preferred shares, debt etc. they made a tonne of money when it was listed in the nasdaq. you think they declare bankruptcy and sell their drug patent for peanuts. the drug if approved by FDA is worth at least a billion.

Doesn't seem logical since the float is 29 mil and they were all issued options at .055 and not a single one has taken them that I could find.
This has a RS hanging out there at up to 150 to 1 so the odds of insiders exercising their options seem remote at best.

It is trading at 2 cents for a reason and it isn't because they are heading back to Nasdaq any time soon.

Those options would reprice themselves to $8.25 if they go with the 150 to 1 RS and I highly doubt any of them are that stupid.

Sorry now it is trading at a penny which is code for BK IMO

Insiders and management own majority of the shares and stand to gain the most if relisting back to nasdaq where min. price is $4/share if relisting on nasdaq. they own millions of shares with current structure. even if the share price was to go to $1 with 54 million shares, ceo and board of directors an management stand to make millions in stock option gains. even without FDA approval of their drug. CEO and management giving themselves free shares like 1.8 million share in stock options. they are instant millionaires if the the relist the stock back to nasdaq.

There is no retail public investors in the otc market or even institutional investors in the otc market like blackstones, vangauards, or fidelity etc. They are banned from investing in otc market stocks.


SOUTH SAN FRANCISCO, Calif., March 11, 2026

Pursuing a Strategy to List on a Major Exchange
Re-establishing our listing on a major exchange remains one of our key priorities. To that end, we have engaged with an investment bank to raise capital and pursue a strategy intended to support a potential relisting on the Nasdaq Capital Market. We believe that our new partner’s institutional relationships and sector expertise align well with our goal of raising sufficient capital in a disciplined manner while attracting longer-term, knowledgeable investors who are familiar with the clinical development landscape and strategic direction. In addition, we are considering other potential paths for relisting on a national securities exchange, including potential business combinations with listed companies, which may include a reverse merger or a business combination with a special purpose acquisition company.

Continued Funding Support
As recently disclosed, as we pursue new financing opportunities and seek to relist on Nasdaq, our lead investor continues to support CERo’s operations through investments in convertible debt. Their commitment to CERo has enabled us to sustain operations and advance our clinical programs. We believe our clinical development and focus on our financing efforts and strategy for relisting on Nasdaq will be beneficial to all CERo stockholders and are grateful for the continued confidence our loyal stockholder base.

Strategic Discussions Regarding Early Data Readouts
We continue to engage in ongoing discussions with potential strategic partners following the most recent data readouts, as is regularly seen in the biotech industry. While these conversations are encouraging, they remain at an early stage and have not resulted in formal agreements. We believe the evolution of our strategy and growing dataset may catalyze future conversations. To the extent permitted under applicable law and contractual obligations, we expect to provide further updates to stockholders should any of these discussions advance in a manner that materially impacts the Company.

Board Expansion – Appointment of Eric Francois
Finally, we recently announced that Eric Francois joined our board of directors. Eric brings decades of experience in life sciences finance, capital markets, and corporate development, including deep expertise in capital raising, M&A, and strategic partnerships. His involvement with the Company is among multiple catalysts that, we believe, will positively impact CERo in the months to come. Eric was instrumental in our discussions with our new investment bank and is already assisting with other potential funding opportunities, operational improvements, and external viewpoints on the Company’s next phase of growth.

Dedicated, Engaged Professionals Working Together to Achieve Success
It should never go without saying that CERo’s world class team – employees, partners, consultants, and advisors – all remain focused and excited about achieving the common goal of improved patient care and improving patients’ lives through innovative clinical development. Despite challenges that might have derailed other companies several times over, the CERo team has continued to perform with enthusiasm toward the achievement of bringing CER-1236 to the next inflection point and beyond.

Our take-home message is clear: CERo is operational, continuing to advance our clinical programs, and generally building momentum. We are committed to transparent communication, and we look forward to sharing the outcomes of each of our ongoing activities in the future. We thank you for your continued support and confidence in our novel approach to treatment and our leadership.

Sincerely,
Chris Ehrlich
CEO
CERo Therapeutics

About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms, including targeting of the TIM-4 ligand. This employs phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.

Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.

Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
https://www.globenewswire.com/newsroom/ti?nf=OTY2OTg0NSM3NDc5MzU4IzUwMDEyNDM5MA==
https://ml.globenewswire.com/media/NGFjMTVkNDctOTJjNi00NjU3LWE1NzItNTJhNzI3ZjM2YWVjLTUwMDEyNDM5MC0yMDI2LTAzLTExLWVu/tiny/CERo-Therapeutics-Holdings-Inc.png

why no comments for over 6 months.
The company is financing and bankrolled by one large investor who keeps diluting the common shares
currently over 54 million shares and if all the preferred shares and debt was to be converted over 300 million shares outstanding.
And no you cannot buy entire company for 1 milllion dollars.
Board of director are being paid with stock options.
Management is paid with stock options too.
One unknown shareholders this company.
Almost no retail shareholders. Insiders don't want the public to buy the commons or don't need retail shareholders at investorshub.
the company doesn't need to be public company to get any financing or investors.

CERO was upgraded to OTCQB this morning

Bought a starter. Why is Ihub showing 8 cents. It closed at .10 ?

CERO, O/S: 1.2 Million share, Extremely Low!

From $11.5 to $0.12, Extremely over over-sold!

Will the company apply for Re-listing?

Up 77% today

A reverse stock split at 1 for 20 then nasqad delisting …..what do you expect

CERO, $11.5 in June, now $0.12.

CERO delisted from the Nasdaq to the OTC. ***PPS dropped 95% from $1.79 to .09 on 45 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

On the pinks 💰💵

Down 90%. Delisting news.

Love those warrants that have years to play and make some giant returns

Cero should be ready for major upticks soon

Also gonna attack the warrants Monday

Gonna start buying Monday.common shares

Interesting float.....

I sold them at 04 last night right before the clothes… I'm gonna add more this morning

😂😂😂 Didn't win on this one?? Surprised lol 😂

Grabbed 5000 warrants at .03.  What are they really worth now?

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

June 17, 2025

https://ih.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/96257758/quantum-biopharma-announces-first-person-with-mult

$CERO

halted, great move doubled in one trade, pure luck. Good luck everyone. From $10.80.

missed 🧨

I'm looking for $22.00🤩

ON FIRE!💥

CERO............................................https://stockcharts.com/h-sc/ui?s=CERO&p=W&b=5&g=0&id=p86431144783









........thx.......................lost intheshuffle............................

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

CER-1236 is currently in Phase 1 clinical trials for AML. The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study has begun with dose escalation to determine highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK).

Chris Ehrlich, CERo CEO, commented, “Orphan Drug Designation underscores the importance of developing new treatments for AML, and the potential for CER-1236 to provide a new and differentiated approach toward treatment. We believe that we are at the forefront of innovation in immuno-oncology and are grateful for the recognition from FDA. We look forward to providing updates on our trial in the near term.”

The FDA's Orphan Drug program is designed to advance the development of drugs that treat a condition affecting 200,000 or fewer US patients annually. ODD status is given to medicinal products that represent a significant benefit over existing treatments and are intended for the treatment of a disease that is life-threatening or chronically debilitating. The ODD designation qualifies CERo and CER-1236 for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee and eligibility for seven years of marketing exclusivity.

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.

The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway.

“On the heels of our recent announcements anticipating the imminent dosing of our first AML patient at MD Anderson Cancer Center and the IND allowance in solid tumors, we are gratified by the support we have received from investors and look forward to continued execution and progress,” said Chris Ehrlich, Chief Executive Officer.

CERO, new 52 week low

CERO, new 52 week low

CERO under $2

@DOMH??? (What irony!!! I just had a Dominari PIZZA for lunch, over here in San Diego!!!)

Tell that to $DOMH wants to run $2.70s now 

CERO DILUTION CRASH AND BURN

CERO: Witty!!! (The MONSTER mystery about YOU, Dude, is why you don't have circa 3,000+ iHub FOLLOWERS by now!!! Seriously!!!)

From CERO $2.53 + 26% to HERO 

CERO READY TO BLAST OFF

CERO POST SPLIT BIO READY TO BEAST

CERO, new 52 week low

CERO new 52 week low

01/07/2025 19:50:00 CERO CERo Therapeutics Holdings Cmn NASDAQ
T1
https://www.nasdaqtrader.com/trader.aspx?id=tradehalts

WRONG BOARD!!! (Meant to say FUBO!!!)

yeah everyone is unloading as fast as they can huge volume falling price...glad for a change i didnt bite lol

CERO: Toilet flush!! (Maybe back up, later.)

yeah down that sux

What is the OS after the R/S